Phase II trial of autologous cell replacement therapy in patients with type-1 diabetes mellitus
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2015
At a glance
- Drugs Cell replacements (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 09 Jun 2015 According to an Orgenesis media release, the company plans to initiate this trial in next 12 - 18 months.
- 10 Apr 2015 Orgenesis has signed a memorandum of understanding with MaSTherCell in Belgium (9165439) and CureCell in South Korea (9177154), so this trial could be in either country.
- 09 Apr 2015 New trial record